A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase

第一阶段研究/基于 DNA 的疫苗与前列腺酸酶的对比

基本信息

  • 批准号:
    6744831
  • 负责人:
  • 金额:
    $ 14.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-01 至 2007-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dr. McNeel will develop a career in patient-oriented translational research with an emphasis on the immunological treatment of patients with prostate cancer. The goal of this proposal is describe both a career training and mentoring plan through which he will receive training in the proper conduct of human subjects research, as well as a translational research plan leading to the conduct of a human vaccine trial for patients with prostate cancer. As part of his career development plan, Dr. McNeel will complete the UW Clinical Investigator Preparatory Pathway (CIPP). This program is an individualized program proviiding didactic and mentored training in the areas of biostatistics and clinical study design, clinical research ethics, leadership and management skills, presentation and teaching skills, scientific writing skills, and expertise within a specific research domain. In addition, he will be mentored directly by Dr. Mark Albertini, a leader in the field of DNA vaccien clinical trials research. His academic and career progress will be followed quarterly by the CIPP Executive Committee as well as Dr. McNeel's faculty mentoring committee at the University of Wisconsin (composed of Drs. Albertini, Sondel, Bryan and Bailey). The other part of this proposal describes a 5-year translational research plan in which Dr. McNeel proposes three aims: 1) to identify the immunological mediators of prostate tissue destruction in a rat model fo inflammatory prostatistics; 2) to identify proteins immunologically recognized in patients with chronic inflammatory prostatis; and 3) to determine in a human clinical vaccine trial the safety and immunological efficacy of a DNA-based vaccine in patients with advanced stage prostate cancer. This clinical trial will target the same antigen, prostatic acid phosphatase, and using the same DNA immunization techniques used to elicit prostatis in the rodent model. This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal.
描述(由申请人提供):McNeel博士将从事以患者为导向的转化研究,重点是前列腺癌患者的免疫治疗。 本提案的目标是描述职业培训和指导计划,通过该计划,他将接受适当进行人类受试者研究的培训,以及转化研究计划,导致对前列腺癌患者进行人类疫苗试验。 作为他职业发展计划的一部分,McNeel博士将完成UW临床研究者预备课程(CIPP)。 该计划是一个个性化的计划,在生物统计学和临床研究设计,临床研究伦理,领导和管理技能,演讲和教学技能,科学写作技能以及特定研究领域的专业知识等领域提供教学和指导培训。此外,他将直接由DNA疫苗临床试验研究领域的领导者Mark Albertini博士指导。 CIPP执行委员会以及威斯康星州大学的McNeel博士的教师指导委员会(由Albertini博士、Sondel博士、Bryan博士和Bailey博士组成)将每季度跟踪他的学术和职业进展。该提案的另一部分描述了一项为期5年的转化研究计划,其中McNeel博士提出了三个目标:1)在大鼠前列腺炎模型中鉴定前列腺组织破坏的免疫介质; 2)鉴定慢性炎性前列腺炎患者中免疫识别的蛋白质;和3)在人临床疫苗试验中确定基于DNA的疫苗在晚期前列腺癌患者中的安全性和免疫功效。该临床试验将靶向相同的抗原,前列腺酸性磷酸酶,并使用与在啮齿动物模型中诱发前列腺炎相同的DNA免疫技术。该试验将作为该提案第二个目标中确定的抗原的临床试验评价的平台和模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DOUGLAS G. MCNEEL其他文献

DOUGLAS G. MCNEEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DOUGLAS G. MCNEEL', 18)}}的其他基金

Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
项目2:雄激素剥夺作为免疫调节疗法与前列腺癌靶向免疫疗法相结合
  • 批准号:
    10555401
  • 财政年份:
    2023
  • 资助金额:
    $ 14.55万
  • 项目类别:
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
分子靶向放射性核素治疗与肿瘤特异性疫苗刺激和扩大 T 细胞激活
  • 批准号:
    10416048
  • 财政年份:
    2020
  • 资助金额:
    $ 14.55万
  • 项目类别:
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
分子靶向放射性核素治疗与肿瘤特异性疫苗刺激和扩大 T 细胞激活
  • 批准号:
    10024886
  • 财政年份:
    2020
  • 资助金额:
    $ 14.55万
  • 项目类别:
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
分子靶向放射性核素治疗与肿瘤特异性疫苗刺激和扩大 T 细胞激活
  • 批准号:
    10672943
  • 财政年份:
    2020
  • 资助金额:
    $ 14.55万
  • 项目类别:
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
分子靶向放射性核素治疗与肿瘤特异性疫苗刺激和扩大 T 细胞激活
  • 批准号:
    10263249
  • 财政年份:
    2020
  • 资助金额:
    $ 14.55万
  • 项目类别:
Effective Anti-Tumor Vaccination - Targeting Checkpoint Regulation at the Time of T-cell Activation
有效的抗肿瘤疫苗——T细胞激活时的靶向检查点调节
  • 批准号:
    9924259
  • 财政年份:
    2017
  • 资助金额:
    $ 14.55万
  • 项目类别:
Androgen Receptor Targeted Vaccines for Prostate Cancer
雄激素受体靶向前列腺癌疫苗
  • 批准号:
    8241125
  • 财政年份:
    2010
  • 资助金额:
    $ 14.55万
  • 项目类别:
Androgen Receptor Targeted Vaccines for Prostate Cancer
雄激素受体靶向前列腺癌疫苗
  • 批准号:
    8453470
  • 财政年份:
    2010
  • 资助金额:
    $ 14.55万
  • 项目类别:
Androgen receptor targeted vaccines for prostate cancer
雄激素受体靶向前列腺癌疫苗
  • 批准号:
    7982767
  • 财政年份:
    2010
  • 资助金额:
    $ 14.55万
  • 项目类别:
Androgen Receptor Targeted Vaccines for Prostate Cancer
雄激素受体靶向前列腺癌疫苗
  • 批准号:
    8657858
  • 财政年份:
    2010
  • 资助金额:
    $ 14.55万
  • 项目类别:

相似海外基金

Autoimmune disorder in hereditary angioedema
遗传性血管性水肿中的自身免疫性疾病
  • 批准号:
    26460654
  • 财政年份:
    2014
  • 资助金额:
    $ 14.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of lymphocyte transmigration across the blood-brain barrier using an in vitro model that mimics blood flow and simulates inflammatory conditions as observed in the most frequent autoimmune disorder of the central nervous system, multiple sclero
使用体外模型模拟血流并模拟在中枢神经系统最常见的自身免疫性疾病多发性硬化症中观察到的炎症状况,从而研究淋巴细胞跨血脑屏障的迁移机制
  • 批准号:
    235301825
  • 财政年份:
    2013
  • 资助金额:
    $ 14.55万
  • 项目类别:
    Research Fellowships
The challenge for the development of therapy for autoimmune disorder by the establishment of artificial thymic medullary organ
人工胸腺髓质器官的建立对自身免疫性疾病治疗发展的挑战
  • 批准号:
    23659241
  • 财政年份:
    2011
  • 资助金额:
    $ 14.55万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了